Logo image
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Journal article   Open access   Peer reviewed

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles

Verena Turco, Kira Pfleiderer, Jessica Hunger, Natalie K Horvat, Kianush Karimian-Jazi, Katharina Schregel, Manuel Fischer, Gianluca Brugnara, Kristine Jähne, Volker Sturm, …
Nature communications, v 14(1), p15
11 Feb 2023
PMID: 36774352
url
https://www.nature.com/articles/s41467-023-36321-6.pdfView
Published, Version of Record (VoR) Open
url
https://doi.org/10.1038/s41467-023-36321-6View
Published, Version of Record (VoR) Open

Abstract

Adjuvants, Immunologic Glioma - drug therapy Humans Macrophages Nanoparticles T-Lymphocytes Toll-Like Receptor 7 - agonists Toll-Like Receptor 8 - agonists Tumor Microenvironment
Glioblastoma, the most common and aggressive primary brain tumor type, is considered an immunologically "cold" tumor with sparse infiltration by adaptive immune cells. Immunosuppressive tumor-associated myeloid cells are drivers of tumor progression. Therefore, targeting and reprogramming intratumoral myeloid cells is an appealing therapeutic strategy. Here, we investigate a β-cyclodextrin nanoparticle (CDNP) formulation encapsulating the Toll-like receptor 7 and 8 (TLR7/8) agonist R848 (CDNP-R848) to reprogram myeloid cells in the glioma microenvironment. We show that intravenous monotherapy with CDNP-R848 induces regression of established syngeneic experimental glioma, resulting in increased survival rates compared with unloaded CDNP controls. Mechanistically, CDNP-R848 treatment reshapes the immunosuppressive tumor microenvironment and orchestrates tumor clearing by pro-inflammatory tumor-associated myeloid cells, independently of T cells and NK cells. Using serial magnetic resonance imaging, we identify a radiomic signature in response to CDNP-R848 treatment and ultrasmall superparamagnetic iron oxide (USPIO) imaging reveals that immunosuppressive macrophage recruitment is reduced by CDNP-R848. In conclusion, CDNP-R848 induces tumor regression in experimental glioma by targeting blood-borne macrophages without requiring adaptive immunity.

Metrics

26 Record Views
43 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Oncology
Logo image